Printer Friendly

BLOOMBERG NEWS INTERVIEW OF IMMUNEX CEO AT 2 P.M.

 BLOOMBERG NEWS INTERVIEW OF IMMUNEX CEO AT 2 P.M.
 Stephen A. Duzan, the CEO of Immunex Corp. (NASDAQ: IMNX), a


biopharmaceutical company, will discuss the outlook for his company at 2:00 p.m. in the Bloomberg Center, 499 Park Avenue, 15th floor, New York. This is the first in a series of Bloomberg interviews with company officials.
 Immunex Corp.'s stock rose approximately 5 points Wednesday. Some of the company's products under development have applications in cancer therapy and treating infectious autoimmune and inflammatory diseases.
 The Bloomberg Center is a state-of-the-art multi media center available for conferences, seminars, interviews and news meetings.
 CONTACT: Elisabeth DeMarse of Bloomberg Financial Markets, 212-318-2024.
 -0- 1/30/92
 (IMNX) CO: IMMUNEX Corp. ST: New York IN: MTC SU: ECO


TS-SM -- NY001B -- 5239 01/30/92 12:23 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 30, 1992
Words:136
Previous Article:THE TRUSTCOMPANY BANCORPORATION REPORTS RECORD EARNINGS
Next Article:HUMAN RESOURCE CONCERNS SHIFT FOR 1992, BNA SURVEY FINDS
Topics:


Related Articles
STATEMENTS MISREPRESENT CISTRON LAWSUIT
Immunex Licenses G-CSF Receptor Patent Rights to SmithKline Beecham
FDA Confirms First Filed Paclitaxel Injection Application
Immunex Chief Financial Officer, Douglas Southern, Retires.
Immunex Promotes Barry G. Pea to Senior Vice President and General Counsel; Scott Hallquist to Focus on Company's Alliance Strategy.
Abgenix and Immunex to Develop Novel Anti-Cancer Antibodies.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters